Newly emerging pharmacologic differences in angiotensin II receptor blockers.

@article{Oparil2000NewlyEP,
  title={Newly emerging pharmacologic differences in angiotensin II receptor blockers.},
  author={Suzanne Oparil},
  journal={American journal of hypertension},
  year={2000},
  volume={13 1 Pt 2},
  pages={
          18S-24S
        }
}
Several angiotensin II receptor blockers (ARB) are currently available for the treatment of hypertension. These drugs share a common mechanism of action-antagonism of angiotensin II AT1 receptors; however, their receptor binding kinetics differ. Candesartan has a higher affinity for the AT1 receptor than all the other ARB. In addition, candesartan and irbesartan block the AT1 receptor with insurmountable antagonism, whereas losartan, valsartan, and eprosartan are competitive antagonists. The… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 29 CITATIONS

Similar Papers

Loading similar papers…